Aero Healthcare Initiates Class II Recall for AEROTAB PAIN RELIEVER Due to Critical Labeling Error
Aero Healthcare has issued a Class II recall for AEROTAB PAIN RELIEVER (NDC 55305-135) nationwide, initiated October 17, 2025. This stems from a critical labeling mix-up where outer packaging incorrectly lists Acetaminophen 500mg and Caffeine 65mg, while inner pouches correctly state Aspirin 500mg and Caffeine 32.5mg. This poses significant patient safety risks, demanding immediate attention from procurement and regulatory teams.
FDA Recall Details: Critical Labeling Discrepancy for AEROTAB PAIN RELIEVER
Aero Healthcare, based in Valley Cottage, NY, has initiated a voluntary Class II recall (D-0155-2026) for its AEROTAB PAIN RELIEVER, effective October 17, 2025. This nationwide recall addresses a significant labeling error on product NDC 55305-135, which includes specific lots #9282 (Exp Date: 2026-09-01) and #9310 (Exp Date: 2026-11-01). The core issue involves a mix-up where the outer box incorrectly declares the active ingredients as Acetaminophen 500mg and Caffeine 65mg. Crucially, the inner pouch accurately identifies the contents as Aspirin (NSAID) 500mg and Caffeine 32.5mg. This discrepancy creates a substantial risk for consumers who may unknowingly ingest Aspirin instead of Acetaminophen. For procurement directors, this incident underscores the imperative of stringent quality control throughout the entire supply chain, extending beyond API sourcing to final packaging and labeling. Regulatory affairs heads must recognize the potential for adverse patient events, particularly for individuals with contraindications to Aspirin, such as bleeding disorders, allergies, or those on anticoagulant therapy. The financial and reputational costs associated with such a recall can be substantial, impacting market access and consumer trust in the long term.
Commercial Implications of a Class II Pharmaceutical Recall
The Class II classification of this recall signifies that the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. However, the specific nature of this labeling error—confusing Aspirin with Acetaminophen—elevates the risk profile due to Aspirin's well-known contraindications and potential for serious side effects in susceptible populations. For supply chain VPs, this recall translates into immediate operational disruptions, including the costly retrieval of affected product from the US nationwide distribution network, potential product destruction, and the administrative burden of managing notifications and customer inquiries. Business development executives must contend with the potential erosion of brand equity for Aero Healthcare and the AEROTAB PAIN RELIEVER product line. Such incidents can lead to a loss of market share, increased scrutiny from retail partners, and a more challenging environment for future product launches. The financial impact extends beyond direct recall costs to include potential legal liabilities arising from patient harm, making robust quality assurance a critical commercial differentiator.
Regulatory Compliance and Quality Control for Over-the-Counter Products
This labeling mix-up points to a fundamental breakdown in Aero Healthcare's quality management system, specifically concerning packaging and labeling controls. The FDA expects strict adherence to Current Good Manufacturing Practice (CGMP) regulations, particularly 21 CFR Part 211, which governs the manufacture, processing, packing, or holding of drugs. Sections like 21 CFR 211.122 (Labeling Issuance) and 21 CFR 211.125 (Labeling Operations) are directly relevant, emphasizing the need for robust procedures to prevent such errors. For regulatory affairs heads, this event necessitates an immediate and comprehensive review of internal Standard Operating Procedures (SOPs) related to labeling, artwork approval, and change control processes. The FDA's scrutiny will extend to Aero Healthcare's root cause analysis and the effectiveness of its corrective and preventive actions (CAPA). Failure to demonstrate adequate remediation could lead to further enforcement actions, impacting the company’s ability to bring new products to market or maintain existing approvals. Procurement directors should mandate similar rigorous quality audits for all their third-party manufacturers and packaging partners to mitigate their own supply chain risks.
Market Dynamics and Procurement Considerations for Pain Relievers
The market for over-the-counter (OTC) pain relievers, including products containing Aspirin, Acetaminophen, and Caffeine, is highly competitive and characterized by broad consumer access. This recall highlights the critical importance of accurate product information in a self-medication environment. For procurement teams, this incident underscores the necessity of diversifying supplier bases for common active pharmaceutical ingredients (APIs) and finished drug products. While specific alternative suppliers for Aero Healthcare are not detailed in our intelligence, the general market for Aspirin and Acetaminophen is robust, with numerous qualified manufacturers globally. Procurement directors should re-evaluate their supplier qualification processes, ensuring they include rigorous assessments of not only API quality but also packaging and labeling integrity. This extends to auditing contract manufacturing organizations (CMOs) and contract packaging organizations (CPOs) to verify their compliance with CGMP and their ability to prevent similar labeling errors. Proactive risk management, including multi-sourcing strategies and robust quality agreements, is essential to maintain supply chain resilience and protect patient safety.
Aero Healthcare's Remediation and Future Compliance Outlook
Following this Class II recall, Aero Healthcare is obligated to provide the FDA with regular updates on the recall's progress and effectiveness, including product reconciliation. The company must conduct a thorough root cause analysis to identify precisely how the labeling mix-up occurred and implement comprehensive corrective and preventive actions (CAPA) to prevent recurrence. This will likely involve re-evaluating their quality control procedures, personnel training, and potentially investing in automated labeling verification systems. For business development executives, the immediate future will involve navigating the reputational damage and rebuilding trust with distributors, retailers, and consumers. The FDA will closely monitor Aero Healthcare's remediation efforts. A failure to adequately address the underlying quality system deficiencies could lead to further regulatory actions, such as increased inspections, or even more severe enforcement. Proactive and transparent communication, coupled with demonstrable improvements in quality assurance, will be crucial for Aero Healthcare to regain its standing and ensure long-term market viability in the highly regulated pharmaceutical sector.